Role of leucine-rich α-2-glycoprotein in Taiwanese patients with inflammatory bowel disease as a predictive biomarker for endoscopic activity

Figure 1 Diagnostic probability of leucine-rich α-2-glycoprotein, C-reactive protein, and fecal calprotectin for detecting active endoscopic disease in patients with inflammatory bowel disease, ulcerative colitis, and Crohn’s disease. A: In patients with inflammatory bowel disease; B: In patients with ulcerative colitis; C: In patients with Crohn’s disease. IBD: Inflammatory bowel disease; FC: Fecal calprotectin; AUC: Area under the curve; LRG: Leucine-rich α-2-glycoprotein; CRP: C-reactive protein; AUROC: Area under the receiver operating characteristic curve; UC: Ulcerative colitis; CD: Crohn’s disease.

Figure 2 Diagnostic probability of leucine-rich α-2-glycoprotein, C-reactive protein, and fecal calprotectin for detecting active endoscopic disease in patients with ulcerative colitis and Crohn’s disease with low C-reactive protein levels. A: In patients with ulcerative colitis with low C-reactive protein levels; B: In patients with Crohn’s disease with low C-reactive protein levels. UC: Ulcerative colitis; CRP: C-reactive protein; FC: Fecal calprotectin; LRG: Leucine-rich α-2-glycoprotein; AUROC: Area under the receiver operating characteristic curve; CD: Crohn’s disease.

Figure 3 Diagnostic probability of the combination of blood-based biomarkers, with or without leucine-rich α-2-glycoprotein, in detecting active endoscopic disease in ulcerative colitis and in the ulcerative colitis with low C-reactive protein subgroup. A: C-reactive protein (CRP) + hemoglobin (Hb) with or without leucine-rich α-2-glycoprotein (LRG) comparison in all ulcerative colitis (UC) patients; B: CRP + Hb + albumin with or without LRG comparison in all UC patients; C: CRP + Hb with or without LRG comparison in UC patients with low CRP (CRP < 0.12 mg/dL); D: CRP + Hb + albumin with or without LRG comparison in UC patients with low CRP (CRP < 0.12 mg/dL). UC: Ulcerative colitis; CRP: C-reactive protein; LRG: Leucine-rich α-2-glycoprotein; Hb: Hemoglobin; AUC: Area under the curve; Alb: Albumin; AUROC: Area under the receiver operating characteristic curve.

Figure 4 Diagnostic probability of the combination of blood-based biomarkers, with or without leucine-rich α-2-glycoprotein, in detecting active endoscopic disease in Crohn’s disease and in the Crohn’s disease with low C-reactive protein subgroup. A: C-reactive protein (CRP) + hemoglobin (Hb) with or without leucine-rich α-2-glycoprotein (LRG) comparison in all Crohn’s disease (CD) patients; B: CRP + Hb + albumin with or without LRG comparison in all CD patients; C: CRP + Hb with or without LRG comparison in CD patients with low CRP (CRP < 0.08 mg/dL); D: CRP + Hb + albumin with or without LRG comparison in CD patients with low CRP (CRP < 0.08 mg/dL). CD: Crohn’s disease; CRP: C-reactive protein; LRG: Leucine-rich α-2-glycoprotein; Hb: Hemoglobin; AUC: Area under the curve; Alb: Albumin; AUROC: Area under the receiver operating characteristic curve.